Flibanserin
Spécifications
167933-07-5Numéro CAS
643-002-2Numéro CE
3-[2-[4-[3-(trifluoromethyl)phenyl]piperazin-1-yl]ethyl]-1H-benzimidazol-2-oneNom IUPAC
C20H21F3N4OFormule chimique
390.4 g/molMasse molaire
Flibanserin; 167933-07-5; Bimt-17; Addyi; Bimt 17; Ectris; Girosa; BIMT 17 BS; BIMT-17-BS; flibanserina; Flibanserine; 1,3-Dihydro-1-(2-(4-(3-(trifluoromethyl)phenyl)-1-piperazinyl)ethyl)-2H-benzimidazol-2-one; 37JK4STR6Z; Female Viagra (Street Name); Female Viagra [Street Name]; 1-(2-(4-(3-Trifluoromethylphenyl)piperazin-1-yl)ethyl)benzimidazol(1H)-2-one; 3-[2-[4-[3-(trifluoromethyl)phenyl]piperazin-1-yl]ethyl]-1H-benzimidazol-2-one; CHEBI:90865; DTXSID30168445; 1-(2-(4-(alpha,alpha,alpha-Trifluoro-m-tolyl)-1-piperazinyl)ethyl)-2-benzimidazolinone; 1-(2-{4-[3-(trifluoromethyl)phenyl]piperazin-1-yl}ethyl)-2,3-dihydro-1H-1,3-benzodiazol-2-one; flibanserinum; 3-(2-(4-(3-(trifluoromethyl)phenyl)piperazin-1-yl)ethyl)-1H-benzimidazol-2-one; 1-(2-(4-(3-(trifluoromethyl)phenyl)piperazin-1-yl)ethyl)-2,3-dihydro-1H-1,3-benzodiazol-2-one; RefChem:57689; G02CX02; DTXCID001781318; MFCD00918402; Filbanserin.; 1-(2-(4-(3-(trifluoromethyl)phenyl)piperazin-1-yl)ethyl)-1H-benzo[d]imidazol-2(3H)-one; 2H-Benzimidazol-2-one, 1,3-dihydro-1-[2-[4-[3-(trifluoromethyl)phenyl]-1-piperazinyl]ethyl]-; 2H-Benzimidazol-2-one,1,3-dihydro-1-[2-[4-[3-(trifluoromethyl)phenyl]-1-piperazinyl]ethyl]-; 1-(2-{4-[3-(trifluoromethyl)phenyl]piperazin-1-yl}ethyl)-1,3-dihydro-2H-benzimidazol-2-one; Flibanserin [USAN]; Flibanserin [USAN:INN]; UNII-37JK4STR6Z; Flibanserin?; Addyi (TN); Flibanserin (Standard); FLIBANSERIN [MI]; FLIBANSERIN [INN]; Flibanserin (USAN/INN); 1-(2-(4-alpha,alpha,alpha-Trifluoro-m-tolyl)-1-piperazinyl)ethyl)-2-benzimidazolinone; FLIBANSERIN [MART.]; FLIBANSERIN [WHO-DD]; Girosa (proposed trade name); SCHEMBL247579; CHEMBL231068; GTPL8182; orb1222623; orb1302975; SCHEMBL29399513; SCHEMBL30249132; HSDB 8278; HY-A0095R; FLIBANSERIN [ORANGE BOOK]; PPRRDFIXUUSXRA-UHFFFAOYSA-N; GLXC-08037; HMS3885K21; HMS5082E03; EX-A2807; HY-A0095; BDBM50476735; EBC-26915; s3716; AKOS005146139; Flibanserin; BIMT-17; BIMT-17BS; CCG-268528; CS-4671; DB04908; FT76243; NCGC00386567-01; NCGC00386567-02; NCGC00386567-03; NCGC00386567-04; DA-53221; SY464953; F1239; F4532; NS00098772; T4297; D02577; EN300-18167232; F857766; L001463; Q415996; BRD-K33637378-001-01-7; 1-(2-(4-alpha,alpha,alpha-Trifluoro-m-tolyl)-1-(piperazinyl)ethyl)-2-benzimidazolinone; 1-[2-[4-(3-trifluoromethylphenyl)piperazin-1-yl]ethyl]benzimidazol-[1H]-2-one; 1-(2-(4-(.ALPHA.,.ALPHA.,.ALPHA.-TRIFLUORO-M-TOLYL)-1-PIPERAZINYL)ETHYL)-2-BENZIMIDAZOLINONE; 1-(2-{4-[3-(Trifluoromethyl)phenyl]piperazin-1-yl}ethyl)-1,3-dihydro-2H-1,3-benzimidazol-2-one; 1-[2-[4-[3-(Trifluoromethyl)phenyl]piperazin-1-yl]ethyl]-1,3-dihydro-2H-benzo[d]imidazol-2-one; 2H-Benzimidazol-2-one, 1,3-dihydro-1-[2-[4-[3-(trifluoromethyl)phenyl]-1-piperazinyl]ethyl]-; BIMT 17; BIMT 17BS; FlibanserinSynonymes
